Format

Send to

Choose Destination
Biotechnol Appl Biochem. 2004 Feb;39(Pt 1):3-16.

Synergies of microtissue design, viral transduction and adjustable transgene expression for regenerative medicine.

Author information

1
Institute of Biotechnology, Swiss Federal Institute of Technology, ETH Hoenggerberg, HPT, CH-8093 Zurich, Switzerland.

Abstract

In the past decade, regenerative medicine has evolved as an interdisciplinary field, integrating expertise from the medical, life- and material-science communities. Recent advances in tissue engineering, gene therapy, gene-function analysis, animal-free drug testing, drug discovery, biopharmaceutical manufacturing and cell-phenotype engineering have capitalized on a core technology portfolio including artificial microtissue design, viral transduction and precise transcription dosing of therapeutic or phenotype-modulating transgenes. We provide a detailed overview on recent progress in these core technologies and comment on their synergistic impact on current and future human therapies.

PMID:
12968952
DOI:
10.1042/BA20030124
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center